These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9394855)

  • 41. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
    Howell A; Robertson JF; Quaresma Albano J; Aschermannova A; Mauriac L; Kleeberg UR; Vergote I; Erikstein B; Webster A; Morris C
    J Clin Oncol; 2002 Aug; 20(16):3396-403. PubMed ID: 12177099
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
    Telford C; Jones N; Livings C; Batson S
    Clin Breast Cancer; 2016 Jun; 16(3):188-95. PubMed ID: 26971303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
    Miller WR; Stuart M; Sahmoud T; Dixon JM
    Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
    Geisler J; King N; Dowsett M; Ottestad L; Lundgren S; Walton P; Kormeset PO; Lønning PE
    Br J Cancer; 1996 Oct; 74(8):1286-91. PubMed ID: 8883419
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New aromatase inhibitors for breast cancer.
    Drug Ther Bull; 1997 Jul; 35(7):55-6. PubMed ID: 9282426
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
    Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
    Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anastrozole: in early breast cancer.
    Wellington K; Faulds DM
    Drugs; 2002; 62(17):2483-90; discussion 2491-2. PubMed ID: 12421108
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.
    Sestak I; Harvie M; Howell A; Forbes JF; Dowsett M; Cuzick J
    Breast Cancer Res Treat; 2012 Jul; 134(2):727-34. PubMed ID: 22588672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
    Kleeberg UR; Dowsett M; Carrion RP; Dodwell DJ; Vorobiof DA; Aparicio LA; Robertson JF
    Oncology; 1997; 54 Suppl 2():19-22. PubMed ID: 9394856
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
    J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
    Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
    Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women.
    Vergote I; Bonneterre J; Thürlimann B; Robertson J; Krzakowski M; Mauriac L; Koralewski L; Webster A; Steinberg M; von Euler M
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S84-5. PubMed ID: 11056332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
    Buzdar AU; Robertson JF; Eiermann W; Nabholtz JM
    Cancer; 2002 Nov; 95(9):2006-16. PubMed ID: 12404296
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anastrozole for breast cancer: recent advances and ongoing challenges.
    Buzdar AU
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer.
    Köberle D; Thürlimann B
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):169-76. PubMed ID: 12113022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anastrozole: a new selective nonsteroidal aromatase inhibitor.
    Goss PE; Tye LM
    Oncology (Williston Park); 1997 Nov; 11(11):1697-703; discussion 1707-8. PubMed ID: 9394367
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
    Bergmann L
    Strahlenther Onkol; 2001 May; 177(5):273-4. PubMed ID: 11398617
    [No Abstract]   [Full Text] [Related]  

  • 60. Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
    Clemett D; Lamb HM
    Drugs; 2000 Jun; 59(6):1279-96. PubMed ID: 10882163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.